Design of multi-epitope vaccine candidate against Brucella type IV secretion system (T4SS)

PLoS One. 2023 Aug 10;18(8):e0286358. doi: 10.1371/journal.pone.0286358. eCollection 2023.

Abstract

Brucellosis is a common zoonosis, which is caused by Brucella infection, and Brucella often infects livestock, leading to abortion and infertility. At present, human brucellosis remains one of the major public health problems in China. According to previous research, most areas in northwest China, including Xinjiang, Tibet, and other regions, are severely affected by Brucella. Although there are vaccines against animal Brucellosis, the effect is often poor. In addition, there is no corresponding vaccine for human Brucellosis infection. Therefore, a new strategy for early prevention and treatment of Brucella is needed. A multi-epitope vaccine should be developed. In this study, we identified the antigenic epitopes of the Brucella type IV secretion system VirB8 and Virb10 using an immunoinformatics approach, and screened out 2 cytotoxic T lymphocyte (CTL) epitopes, 9 helper T lymphocyte (HTL) epitopes, 6 linear B cell epitopes, and 6 conformational B cell epitopes. These advantageous epitopes are spliced together through different linkers to construct a multi-epitope vaccine. The silico tests showed that the multi-epitope vaccine was non-allergenic and had a strong interaction with TLR4 molecular docking. In immune simulation results, the vaccine construct may be useful in helping brucellosis patients to initiate cellular and humoral immunity. Overall, our findings indicated that the multi-epitope vaccine construct has a high-quality structure and suitable characteristics, which may provide a theoretical basis for the development of a Brucella vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brucella*
  • Brucellosis* / prevention & control
  • Computational Biology / methods
  • Epitopes, B-Lymphocyte
  • Epitopes, T-Lymphocyte
  • Humans
  • Molecular Docking Simulation
  • Type IV Secretion Systems
  • Vaccines*
  • Vaccines, Subunit

Substances

  • Type IV Secretion Systems
  • Epitopes, B-Lymphocyte
  • Vaccines
  • Epitopes, T-Lymphocyte
  • Vaccines, Subunit

Grants and funding

This study was supported by grants (No. 81860352, No.81860375, No.81560322) from the National Natural Science Foundation of China and funds for the Xinjiang Key construction Project of the 13th Five-Year Plan (basic medicine) and Tianshan Youth Talent Program of Xinjiang Uygur Autonomous Region, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund (SKL-HIDCA2021-JH11, https://caskl.xjmu.edu.cn/)","Xinjiang Uygur Autonomous Region science and technology support project (2022E02061, http://kjt.xinjiang.gov.cn/kjt/c100870/201111/acd5ead987f945cba2498ce413a36388.shtml)" and "Youth Science and technology top talent Program (2022TSYCCX0112, http://kjt.xinjiang.gov.cn/kjt/c100870/201111/acd5ead987f945cba2498ce413a36388.shtml) ". Author: F.B Zhang. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.